Carotid Artery Disease

3
Pipeline Programs
2
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
6 programs
1
Carotid artery stenting with filterPhase 41 trial
Carotid artery stenting with filterN/A1 trial
RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6N/A1 trial
RX ACCULINK, RX ACCUNET Embolic Protection SystemN/A1 trial
RX Acculink Carotid Stent SystemN/A1 trial
+1 more programs
Active Trials
NCT00106938Terminated1,663Est. Mar 2013
NCT00406055Completed18,855Est. Jun 2012
NCT00302237Completed6,426Est. May 2010
+3 more trials
C
CordisFL - Miami Lakes
2 programs
2
-PRECISE Nitinol Stent SystemPhase 31 trial
Cordis Nitinol StentPhase 31 trial
Active Trials
NCT00231231Completed1,500Est. Nov 2006
NCT00231270Completed1,300Est. Aug 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottCarotid artery stenting with filter
Cordis-PRECISE Nitinol Stent System
CordisCordis Nitinol Stent
AbbottRX Acculink Carotid Stent System
AbbottXact Stent with either Emboshield Pro
AbbottRX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
AbbottRX ACCULINK, RX ACCUNET Embolic Protection System
AbbottCarotid artery stenting with filter

Clinical Trials (8)

Total enrollment: 32,769 patients across 8 trials

NCT00287508AbbottCarotid artery stenting with filter

Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)

Start: Nov 2005Est. completion: Jan 20081,500 patients
Phase 4Completed
NCT00231231Cordis-PRECISE Nitinol Stent System

Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)

Start: Sep 2004Est. completion: Nov 20061,500 patients
Phase 3Completed
NCT00231270CordisCordis Nitinol Stent

Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)

Start: Aug 2000Est. completion: Aug 20051,300 patients
Phase 3Completed
NCT01445613AbbottRX Acculink Carotid Stent System

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

Start: Oct 2011Est. completion: Mar 20161,203 patients
N/ACompleted
NCT00402740AbbottXact Stent with either Emboshield Pro

Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)

Start: Nov 2006Est. completion: Oct 2011322 patients
N/ACompleted
NCT00406055AbbottRX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6

CHOICE: Carotid Stenting For High Surgical-Risk Patients

Start: Oct 2006Est. completion: Jun 201218,855 patients
N/ACompleted
NCT00302237AbbottRX ACCULINK, RX ACCUNET Embolic Protection System

CAPTURE 2 Post-Marketing Registry

Start: Mar 2006Est. completion: May 20106,426 patients
N/ACompleted
NCT00106938AbbottCarotid artery stenting with filter

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

Start: Apr 2005Est. completion: Mar 20131,663 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space